Volver a News
NOTICIA
GA_P advises the issuer on the IPO of Labiana Health
24 de May, 2022
Gómez-Acebo & Pombo has advised the issuer in the IPO process of Labiana Health. The company will be the first Spanish veterinary company to enter the market and expects to be listed on BME Growth in mid-June through a capital increase.
Labiana is an animal and human health platform, aimed at raising capital to accelerate its organic and inorganic growth. The company already has a firm commitment from Inveready, which, through a convertible bond, will invest up to 4 million subject to completing the IPO. Labiana’s roadmap envisages issuing new shares equivalent to 30% or 40% of its share capital to raise a significant amount of money that will be used to boost the growth that the group has been experiencing in recent years.
Augusto Piñel, Jacobo Palanca, Emiliano Moreno and Irene Carreño Uría, Mercantil partner and associates, have advised on the transaction.
Labiana is an animal and human health platform, aimed at raising capital to accelerate its organic and inorganic growth. The company already has a firm commitment from Inveready, which, through a convertible bond, will invest up to 4 million subject to completing the IPO. Labiana’s roadmap envisages issuing new shares equivalent to 30% or 40% of its share capital to raise a significant amount of money that will be used to boost the growth that the group has been experiencing in recent years.
Augusto Piñel, Jacobo Palanca, Emiliano Moreno and Irene Carreño Uría, Mercantil partner and associates, have advised on the transaction.
Abogado mencionado
Augusto Piñel – Partner
Jacobo Palanca – Senior Associate
Ver todos los abogados
Ver menos abogados
Tipología
Deal
More information about
Gómez-Acebo & Pombo
13 Apr, 2026 
PUBLICACIÓN
21 Sep, 2026
Pharma & Healthcare No. 50
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
21 Sep, 2026 
PUBLICACIÓN
23 Jun, 2026
Pharma & Healthcare No. 49
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
23 Jun, 2026
PUBLICACIÓN
18 Jun, 2026
Royal Decree 415/2026: key aspects of the new health technology assessment system
Royal Decree 415/2026 establishes a unified framework for the assessment of health technologies in Spain, distinguishing between the technical assessment and the administrative decision regarding funding, pricing or inclusion in the service catalogue, and incorporating the requirements of Regulation (EU) 2021/2282. The aspect that raises the most legal questions in this new piece of legislation is the connection between the assessment regulated by the Royal Decree and the procedures for funding, pricing, and inclusion in the service catalogue.
18 Jun, 2026
PUBLICACIÓN
30 Apr, 2026
Pharma & Healthcare No. 48
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
30 Apr, 2026
PUBLICACIÓN
06 Mar, 2026
The long arm of the Unified Patent Court based on the "event giving rise to the infringement" and considerations on the application of lex loci protectionis
This paper analyses the decision of the Mannheim Local Division of 2 October 2025, where the Unified Patent Court (UPC) justifies its jurisdiction on the basis of shipment of products from a UPC territory by company listed as authorized representative in the EC and UK markets as event giving rise to damage. Furthermore, although the applicable law with regard to the infringement of the European patent validated in States that are not party to the Agreement on a Unified Patent Court is the national law of those States, with regard to the scope of patent protection, the UPC imposes on the defendant—unduly—the burden of proving the specifics of national law.
06 Mar, 2026
PUBLICACIÓN
03 Mar, 2026
Legal doctrine of the UPC’s Court of Appeal on the patent invalidity defence: is the way in which the ‘long arm’ is applied compatible with the UPC's own Rules of Procedure?
The Court of Appeal of the Unified Patent Court has ruled that a patent invalidity defence cannot be raised before the Unified Patent Court, with only a counterclaim being possible. This calls into question the way in which the ‘long arm’ is being applied with regard to European patents validated in States that are not party to the Agreement on a Unified Patent Court (UPCA), whether or not they are members of the European Union, since no counterclaim for revocation or plea of invalidity as a defence can be filed or raised with regard to such patents. This raises significant doubts about the compatibility of how the ‘long arm’ is applied in the Unified Patent Court system, given its own Rules of Procedure.
03 Mar, 2026
PUBLICACIÓN
26 Feb, 2026
Pharma & Healthcare No. 47
The newsletter covers the main developments in Pharma & Healthcare legislation and case law.
26 Feb, 2026
PUBLICACIÓN
27 Jan, 2026
Jurisdiction of national courts of States party to the Agreement on a Unified Patent Court in respect of actions relating to classic European patents during the transitional period
During the transitional period of the Agreement on a Unified Patent Court, national courts retain jurisdiction to hear cases concerning classic European patents, without the need for the proprietor to have exercised the opt-out option, i.e. without the need to have excluded the jurisdiction of the Unified Patent Court over such patents. However, the Venice Court ruling discussed here considers that national courts may only be used if the opt-out has been exercised, contradicting the provisions of Article 83 of the Agreement.
27 Jan, 2026
PUBLICACIÓN
21 Jan, 2026
Incompatibility between practising a healthcare profession and having a pecuniary interest in the manufacture or sale of medicinal products or medical devices
Royal Legislative Decree 1/2015, of 24 July, approving the recast version of the Medicinal Products and Medical Devices (Guarantees and Rational Use) Act, prohibits healthcare professionals with prescribing powers from having a direct pecuniary interest in activities related to medicines. This prohibition does not extend to indirect interests, as distinguished in Article 4 of said legislative decree. Judgment no. 483/2025 of the High Court of Justice of the Basque Country concludes that mere membership of a group of companies does not entail incompatibility if each entity retains real autonomy.
21 Jan, 2026